Imugene doses first Australian subject in trial of B-cell lymphoma drug candidate
The subject was dosed at the Royal Prince Alfred Hospital in Sydney, Australia.
Cytiva Pipe dream to pipeline WP 3
Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership
Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint
Sensorion completes first cohort enrolment in Phase I/II gene therapy trial
Adicet Bio doses first subject in Phase I trial of renal cell carcinoma therapy
FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment
BrightPath and Cellistic partner for clinical trial advancements of CAR-T cell therapy
FDA clears SpliceBio’s IND application to begin Stargardt disease therapy trial
